Related Experiment Video
Updated: Apr 16, 2026
Molecular Profiling of the Invasive Tumor Microenvironment in a 3-Dimensional Model of Colorectal Cancer Cells and Ex vivo Fibroblasts
Published on: April 29, 2014
Cancer Research UK Centre for Drug Development: translating 21st-century science into the cancer medicines of
James W A Ritchie1, Robert J Williams1
1Centre for Drug Development, Cancer Research UK, Angel Building, 407 St John Street, London EC1V 4AD, UK.
Abstract:
The Cancer Research UK Centre (CRUK) for Drug Development (CDD) can trace its origins back to the Cancer Research Campaign Phase I/II Committee (created in 1980) and to date has tested over 120 potential cancer medicines in early-phase clinical trials. Five drugs are now registered, providing benefit to thousands of patients with cancer as part of their routine standard of care. In recent years, the CDD has established several different business and operating models that provide it with access to the pipelines of pharmaceutical and biotechnology companies. This has enabled potential new treatments to be taken into clinical development that might have otherwise languished on companies' shelves and has increased the number of drug combinations being explored in early-phase clinical trials.
Insights
The Cancer Research UK Centre for Drug Development has advanced over 120 cancer drugs into early trials, with five now standard care. New models enhance access to industry drug pipelines for clinical development.
Area of Science:
- Oncology
- Drug Development
- Clinical Trials
Background:
- The Cancer Research UK Centre for Drug Development (CDD) has a long history, originating from the Cancer Research Campaign Phase I/II Committee in 1980.
- The CDD has evaluated over 120 potential cancer therapeutics in early-phase clinical trials.
